PDCD1 and breast cancer: Last but not least, we also performed a study of immune checkpoint expression and medication sensitivity; the results revealed that immune checkpoint expression increased in the majority of low-risk BC patients, suggesting that low-risk BC patients may be more responsive to PD-1/L1 immunotherapy.